NeuroPace Inc (NAS:NPCE)

Q3 2024 Neuropace Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT

Release Date Price: $7.14 (-1.92%)

Transcript 10-Q8-K

Key Points

Positve

NeuroPace Inc (NPCE) reported a record revenue of $21.1 million for Q3 2024, marking a 28% increase compared to the same period last year.
The company demonstrated disciplined operating expense management, reducing cash burn to $1.8 million for the quarter.
NeuroPace Inc (NPCE) increased its cash balance from $55.5 million at the end of Q2 to $56.8 million at the end of Q3, indicating strong financial health.
The company successfully expanded its market penetration and utilization of both the RNS system and Dixie Medical products.
NeuroPace Inc (NPCE) is on track with its Nautilus study, which could lead to the RNS system being the first device with an FDA-approved indication for idiopathic generalized epilepsy.

Negative

Gross margin for Q3 2024 was 73.2%, slightly down from 74.5% in the same quarter of 2023.
R&D expenses increased to $5.8 million in Q3 2024 from $4.8 million in the same period of 2023, driven by personnel and program expenses.
SG&A expenses rose to $13.9 million in Q3 2024, up from $13.4 million in the prior year period.
The company reported a net loss of $5.5 million for Q3 2024, although this was an improvement from a $7.3 million loss in Q3 2023.
There is potential quarter-to-quarter variability in revenue growth, which could impact future financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NPCE.OQ - Neuropace Inc
Q3 2024 Neuropace Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the No third quarter, 2024 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad.

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Investor Relations. Thank you, sir. You may be in good.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Afternoon. Thank you for joining us for Neuropace's third

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.